Reference Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach
No data available in table

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role
No data available in table

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
No data available in table

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
No data available in table

Filter rows:

Showing 1 to 134 of 134 entries

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance
FGFR2	R6P	missense	no effect - predicted	FGFR2 R6P does not lie within any known functional domains of the Fgfr2 protein (UniProt.org). R6P results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR1	A21T	missense	no effect - predicted	FGFR1 A21T lies within the signal peptide region of the Fgfr1 protein (UniProt.org). A21T results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR1	T26I	missense	no effect - predicted	FGFR1 T26I lies within Ig-like C2-type domain 1 of the Fgfr1 protein (UniProt.org). T26I results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR2	L33S	missense	unknown	FGFR2 L33S lies within Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). L33S results in decreased proliferation in a competition assay but transformation activity similar to wild-type Fgfr2 in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr2 protein function is unknown.
FGFR2	C62Y	missense	gain of function - predicted	FGFR2 C62Y lies within Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). C62Y results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR3	P63S	missense	no effect - predicted	FGFR3 P63S lies within Ig-like C2-type domain 1 of the Fgfr3 protein (UniProt.org). P63S results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR3	G66fs	frameshift	no effect - predicted	FGFR3 G66fs results in a change in the amino acid sequence of the Fgfr3 protein beginning at aa 66 of 806, likely resulting in premature truncation of the functional protein (UniProt.org). G66fs results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	A67V	missense	gain of function - predicted	FGFR2 A67V lies within Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). A67V results in decreased proliferation relative to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR3	T79S	missense	no effect - predicted	FGFR3 T79S lies within Ig-like C2-type domain 1 of the Fgfr3 protein (UniProt.org). T79S results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	N82K	missense	gain of function - predicted	FGFR2 N82K lies within Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). N82K results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	D101Y	missense	gain of function	FGFR2 D101Y lies within the extracellular Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). D101Y results in a growth advantage relative to wild-type Fgfr2 in a competition assay (PMID: 34272467) and increased transformation activity in cultured cells (PMID: 34272467, PMID: 18552176).
FGFR1	A121D	missense	no effect - predicted	FGFR1 A121D lies within the extracellular domain of the Fgfr1 protein (UniProt.org). A121D results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR1	S125L	missense	no effect - predicted	FGFR1 S125L lies within the extracellular domain of the Fgfr1 protein (UniProt.org). S125L results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR1	D128N	missense	no effect - predicted	FGFR1 D128N lies within the extracellular domain of the Fgfr1 protein (UniProt.org). D128N results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR1	D128V	missense	unknown	FGFR1 D128V lies within the extracellular domain of the Fgfr1 protein (UniProt.org). D128V results in altered proliferation relative to wild-type Fgfr1 in a competition assay, but results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr1 protein function is unknown.
FGFR1	D133N	missense	no effect - predicted	FGFR1 D133N lies within the extracellular domain of the Fgfr1 protein (UniProt.org). D133N results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR3	E140K	missense	no effect - predicted	FGFR3 E140K lies within the extracellular domain of the Fgfr3 protein (UniProt.org). E140K results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR1	T141R	missense	no effect - predicted	FGFR1 T141R lies within the extracellular domain of the Fgfr1 protein (UniProt.org). T141R results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR1	P150S	missense	unknown	FGFR1 P150S lies within the extracellular domain of the Fgfr1 protein (UniProt.org). P150S results in altered proliferation relative to wild-type Fgfr1 in a competition assay, but results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr1 protein function is unknown.
FGFR2	E160K	missense	gain of function - predicted	FGFR2 E160K lies within Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). E160K results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	E163K	missense	gain of function - predicted	FGFR2 E163K lies within Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). E163K results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	M186T	missense	loss of function - predicted	FGFR2 M186T lies within Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). M186T is a common Fgfr2 polymorphism (PMID: 11781872, PMID: 25129254) that results in similar cell proliferation and viability levels as wild-type Fgfr2 (PMID: 29533785), and proliferation similar to wild-type in a competition assay, but decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr2 protein function.
FGFR1	R189C	missense	unknown	FGFR1 R189C lies within Ig-like C2-type domain 2 of the Fgfr1 protein (UniProt.org). R189C results in an increased growth advantage in a competition assay but transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr1 protein function is unknown.
FGFR1	N193fs	frameshift	loss of function - predicted	FGFR1 N193fs results in a change in the amino acid sequence of the Fgfr1 protein beginning at aa 193 of 822, likely resulting in premature truncation of the functional protein (UniProt.org). N193fs results in decreased proliferation relative to wild-type Fgfr1 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr1 protein function.
FGFR3	E194K	missense	no effect - predicted	FGFR3 E194K lies within Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). E194K results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	R203C	missense	gain of function	FGFR2 R203C lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). R203C results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), but confers a gain of function to the Fgfr2 protein, as demonstrated by increased autophosphorylation, increased phosphorylation of FRS2, and increased activation of Mek1/2 and Stat3 upon FGF1 stimulation in cell culture (PMID: 23527311).
FGFR2	R203H	missense	unknown	FGFR2 R203H lies within Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). R203H results in decreased proliferation relative to wild-type Fgfr2 in a competition assay but transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr2 protein function is unknown.
FGFR3	Q209H	missense	no effect - predicted	FGFR3 Q209H lies within Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). Q209H results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	R210Q	missense	unknown	FGFR2 R210Q lies within Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). R210Q results in decreased proliferation relative to wild-type Fgfr2 in a competition assay but transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr2 protein function is unknown.
FGFR2	Q212K	missense	gain of function - predicted	FGFR2 Q212K lies within Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). Q212K results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	G227E	missense	unknown	FGFR2 G227E lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). The functional effect of G227E is conflicting, as it has been reported to impair receptor processing and trafficking to the cell membrane and reduce ligand-dependent cell proliferation in one study (PMID: 19147536), similar cell proliferation and viability levels to wild-type Fgfr2 in two different cell lines in another study (PMID: 29533785), and a growth advantage relative to wild-type Fgfr2 in a competition assay but transformation activity similar to wild-type Fgfr2 in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr2 protein function is unknown.
FGFR1	S238N	missense	no effect - predicted	FGFR1 S238N lies within Ig-like C2-type domain 2 of the Fgfr1 protein (UniProt.org). S238N results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR2	H242Y	missense	no effect - predicted	FGFR2 H242Y lies within Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). H242Y results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR3	R248H	missense	no effect - predicted	FGFR3 R248H lies within the extracellular domain of the Fgfr3 protein (UniProt.org). R248H results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR3	R248_S249insC	insertion	gain of function - predicted	FGFR3 R248_S249insC results in the insertion of a cystine (C) in the extracellular domain of the Fgfr3 protein between amino acids 248 and 249 (UniProt.org). R248_S249insC results in a growth advantage in a competition assay and increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr3 protein function.
FGFR3	S249C	missense	gain of function	FGFR3 S249C lies within the linker region between IgD2 and IgD3 of the Fgfr3 protein (PMID: 19381019). S249C results in stabilized homodimer formation and constitutive Fgfr3 phosphorylation in vitro (PMID: 17384684), ligand-independent cell proliferation in culture (PMID: 19381019, PMID: 29533785), increased Akt signaling (PMID: 31316618), a growth advantage relative to wild-type Fgfr3 in a competition assay, and increased transformation activity in cultured cells (PMID: 34272467).	Y
FGFR1	R250W	missense	unknown	FGFR1 R250W lies within the D2-D3 linker region of the Fgfr1 protein (PMID: 23276709). R250W results in similar cell proliferation and viability levels to wild-type Fgfr1 in two different cell lines in culture in one study (PMID: 29533785), decreased proliferation relative to wild-type Fgfr1 in a competition assay, and transformation activity similar to wild-type Fgfr1 in another study (PMID: 34272467), and therefore, its effect on Fgfr1 protein function is unknown.
FGFR2	R251Q	missense	loss of function	FGFR2 R251Q lies within the region linking Ig-like domains II and III of the Fgfr2 protein (PMID: 11121055). R251Q results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), but confers a loss of function on the Fgfr2 protein as demonstrated by loss of ligand binding and diminished Mapk activation upon Fgf2 stimulation in cell culture (PMID: 19147536).
FGFR2	S252W	missense	gain of function - predicted	FGFR2 S252W lies within the extracellular domain of the Fgfr2 protein (UniProt.org). S252W results in a growth advantage relative to wild-type Fgfr2 in a competition assay and transformation activity similar to overexpressed Fgfr2 in cultured cells (PMID: 34272467), and results in loss of ligand specificity, increased Fgfr2 phosphorylation, increased FGF7-stimulated shedding of HB-EGF, and is transforming in cell culture (PMID: 11121055, PMID: 18552176, PMID: 37759450), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	P253L	missense	gain of function - predicted	FGFR2 P253L lies within the extracellular domain of the Fgfr2 protein (UniProt.org). P253L does not confer growth advantage over wild-type Fgfr2 in a competition assay, but results in increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	P253R	missense	gain of function - predicted	FGFR2 P253R lies within the extracellular domain of the Fgfr2 protein (UniProt.org). P253R results in transformation activity similar to wild-type Fgfr2 in one study (PMID: 34272467), but a growth advantage relative to wild-type Fgfr2 in a competition assay (PMID: 34272467), loss of ligand specificity, activation of the p38/MAPK pathway in transgenic mouse models, and is transforming in cell culture (PMID: 11121055, PMID: 20175913, PMID: 23786770), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR3	A257V	missense	no effect - predicted	FGFR3 A257V lies within Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). A257V results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	Q259*	nonsense	loss of function - predicted	FGFR2 Q259* results in a premature truncation of the Fgfr2 protein at amino acid 259 of 821 (UniProt.org). Q259* results in similar cell proliferation and viability levels as wild-type Fgfr2 in two different cell lines (PMID: 29533785), but decreased proliferation relative to wild-type Fgfr2 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr2 protein function.
FGFR2	A264T	missense	gain of function - predicted	FGFR2 A264T lies within Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). A264T results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR3	A265T	missense	no effect - predicted	FGFR3 A265T lies within Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). A265T results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR3	A265V	missense	no effect - predicted	FGFR3 A265V lies within Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). A265V results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR1	A268S	missense	no effect - predicted	FGFR1 A268S lies within Ig-like C2-type domain 3 of the Fgfr1 protein (UniProt.org). A268S results in similar cell proliferation and viability levels as wild-type Fgfr1 (PMID: 29533785) and transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR3	P283S	missense	no effect - predicted	FGFR3 P283S lies within Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). P283S results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR3	H284fs	frameshift	gain of function - predicted	FGFR3 H284fs results in a change in the amino acid sequence of the Fgfr3 protein beginning at aa 284 of 806, likely resulting in premature truncation of the functional protein (UniProt.org). H284fs results in proliferation similar to wild-type Fgfr3 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr3 protein function.
FGFR2	W290C	missense	gain of function	FGFR2 W290C lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). W290C does not result in increased Fgfr2 phosphorylation, but increases both ligand-dependent and ligand-independent dimerization of Fgfr2 (PMID: 23786770), results in a growth advantage relative to wild-type Fgfr2 in a competition assay (PMID: 34272467), is transforming in cell culture (PMID: 23786770, PMID: 34272467), and promotes tumor formation in xenograft models (PMID: 23786770).
FGFR2	P303L	missense	no effect - predicted	FGFR2 P303L lies within Ig-like C2-type domain 3 of the Fgfr2 protein (UniPort.org). P303L results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR2	G305R	missense	no effect - predicted	FGFR2 G305R lies within Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). G305R results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR2	K310R	missense	gain of function - predicted	FGFR2 K310R lies within Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). K310R results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR3	T311fs	frameshift	no effect - predicted	FGFR3 T311fs results in a change in the amino acid sequence of the Fgfr3 protein beginning at aa 311 of 806, likely resulting in premature truncation of the functional protein (UniProt.org). T311fs results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR1	T319A	missense	loss of function - predicted	FGFR1 T319A lies within Ig-like C2-type domain 3 of the Fgfr1 protein (UniProt.org). T319A results in decreased proliferation relative to wild-type Fgfr1 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr1 protein function.
FGFR1	D320N	missense	unknown	FGFR1 D320N lies within Ig-like C2-type domain 3 of the Fgfr1 protein (UniProt.org). D320N results in decreased proliferation relative to wild-type Fgfr1 in a competition assay but transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr1 protein function is unknown.
FGFR3	E322K	missense	no effect - predicted	FGFR3 E322K lies within Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). E322K results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	Y328N	missense	gain of function - predicted	FGFR2 Y328N lies within Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). Y328N results in decreased proliferation in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	R330W	missense	no effect - predicted	FGFR2 R330W lies within Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). R330W results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR1	T340M	missense	no effect - predicted	FGFR1 T340M lies within Ig-like C2-type domain 3 of the Fgfr1 protein (UniProt.org). T340M results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR3	G346E	missense	no effect - predicted	FGFR3 G346E lies within Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). G346E results in reduced dimer formation, but demonstrates similar Fgfr3 autophosphorylation to wild-type in the absence of ligand in culture (PMID: 22529939), proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	G364E	missense	gain of function - predicted	FGFR2 G364E lies within the extracellular domain of the Fgfr2 protein (UniProt.org). G364E results in decreased proliferation in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR3	G370C	missense	gain of function	FGFR3 G370C lies within the juxtamembrane region of the Fgfr3 protein (PMID: 12009017). G370C confers a gain of function to the Fgfr3 protein as demonstrated by increased Fgfr3 phosphorylation, constitutive activation of the Mapk signaling pathway (PMID: 12009017), a growth advantage relative to wild-type Fgfr3 in a competition assay, and increased transformation activity in cultured cells (PMID: 34272467).
FGFR2	A371V	missense	no effect - predicted	FGFR2 A371V lies within the extracellular domain of the Fgfr2 protein (UniProt.org). A371V results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR3	S371C	missense	gain of function	FGFR3 S371C lies within the extracellular domain of the Fgfr3 protein (UniProt.org). S371C confers a gain of function to the Fgfr3 protein as demonstrated by dimerization, constitutive activation, increased MAPK pathway signaling (PMID: 12009017), a growth advantage relative to wild-type Fgfr3 in a competition assay, and increased transformation activity in cultured cells (PMID: 34272467).
FGFR3	Y373C	missense	gain of function	FGFR3 Y373C lies within the extracellular domain of the Fgfr3 protein (UniProt.org). Y373C confers a gain of function to the Fgfr3 protein resulting in increased proliferation relative to wild-type Fgfr3 in a competition assay (PMID: 34272467), constitutive activation, downstream signaling (PMID: 11429702, PMID: 11157491), and transformation of cultured cells (PMID: 11429702, PMID: 11157491, PMID: 34272467).
FGFR2	Y375C	missense	gain of function	FGFR2 Y375C lies within the extracellular juxtamembrane domain of the Fgfr2 protein (PMID: 17525745). Y375C results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), but constitutive phosphorylation of Fgfr2 in cell culture, activation of Mapk p38 signaling, and abnormal proliferation and differentiation in the skin and skull of transgenic mouse models (PMID: 22585574).
FGFR3	G380E	missense	gain of function - predicted	FGFR3 G380E lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). G380E results in a growth advantage in a competition assay and increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr3 protein function.
FGFR2	C382R	missense	gain of function	FGFR2 C382R (also referred to as C383R) lies within the helical domain of the Fgfr2 protein (UniProt.org). C382R results in proliferation similar to wild-type Fgfr2 in a competition assay (PMID: 34272467), but confers a gain of function on the Fgfr2 protein, as demonstrated by constitutive MAPK pathway activation (PMID: 24993163), and transformation of cells in culture (PMID: 24993163, PMID: 34272467).
FGFR3	F384L	missense	no effect	FGFR3 F384L lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). F384L results in proliferation similar to wild-type Fgfr3 in a competition assay, transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), does not result in activation of Fgfr3, and is not transforming in cell culture (PMID: 11157491, PMID: 29533785).
FGFR2	A389T	missense	unknown	FGFR2 A389T lies within the transmembrane domain of the Fgfr2 protein (UniProt.org). A389T results in proliferation similar to wild-type Fgfr2 in a competition assay (PMID: 34272467) and is not transforming in culture in one study (PMID: 18552176), but increased transformation activity in cultured cells in another study (PMID: 34272467), and therefore, its effect on Fgfr2 protein function is unknown.
FGFR3	A391E	missense	gain of function	FGFR3 A391E (also referred to as A393E from the FGFR3IIIb isoform) lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). A391E results in increased dimerization, ligand-independent activation of Fgfr3 in cell culture (PMID: 21536014, PMID: 23437153), increased proliferation in a competition assay, and increased transformation activity in cultured cells (PMID: 34272467).
FGFR3	A391V	missense	gain of function - predicted	FGFR3 A391V lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). A391V results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785), but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr3 protein function.
FGFR2	V392A	missense	gain of function - predicted	FGFR2 V392A lies within the transmembrane domain of the Fgfr2 protein (UniProt.org). V392A results in decreased proliferation relative to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	V395D	missense	no effect - predicted	FGFR2 V395D lies within the transmembrane domain of the Fgfr2 protein (UniProt.org). V395D results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR2	R399*	nonsense	loss of function - predicted	FGFR2 R399* results in a premature truncation of the Fgfr2 protein at amino acid 399 of 821 (UniProt.org). R399* results in decreased proliferation relative to wild-type Fgfr2 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr2 protein function.
FGFR2	R399Q	missense	gain of function - predicted	FGFR2 R399Q lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). R399Q results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR3	K403fs	frameshift	no effect - predicted	FGFR3 K403fs results in a change in the amino acid sequence of the Fgfr3 protein beginning at aa 403 of 806, likely resulting in premature truncation of the functional protein (UniProt.org). K403fs results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	H416R	missense	gain of function - predicted	FGFR2 H416R lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). H416R results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	I422V	missense	gain of function - predicted	FGFR2 I422V lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). I422V results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR1	S436F	missense	loss of function - predicted	FGFR1 S436F lies within the cytoplasmic domain of the Fgfr1 protein (UniProt.org). S436F results in proliferation similar to wild-type in a competition assay but decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr1 protein function.
FGFR1	R445W	missense	unknown	FGFR1 R445W lies within the cytoplasmic domain of the Fgfr1 protein (UniProt.org). R445W results in decreased proliferation relative to wild-type Fgfr1 in a competition assay but transformation activity similar to wild-type Fgfr1 in culture (PMID: 34272467), and therefore, its effect on Fgfr1 protein function is unknown.
FGFR1	M456V	missense	no effect - predicted	FGFR1 M456V lies within the cytoplasmic domain of the Fgfr1 protein (UniProt.org). M456V results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR1	E467K	missense	no effect - predicted	FGFR1 E467K lies within the cytoplasmic domain of the Fgfr1 protein (UniProt.org). E467K results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR2	D471N	missense	no effect - predicted	FGFR2 D471N lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). D471N results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR2	E475K	missense	unknown	FGFR2 E475K lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). E475K results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), but demonstrates slightly increased Fgfr2 kinase activity, and also decreases protein stability and cell proliferation in culture (PMID: 19147536), and therefore, its effect on Fgfr2 protein function is unknown.
FGFR1	R475Q	missense	no effect - predicted	FGFR1 R475Q lies within the cytoplasmic domain of the Fgfr1 protein (UniProt.org). R475Q results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR1	P483L	missense	no effect - predicted	FGFR1 P483L lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). P483L results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR2	G542E	missense	loss of function - predicted	FGFR2 G542E lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). G542E results in decreased proliferation relative to wild-type Fgfr2 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr2 protein function.
FGFR2	H544Q	missense	gain of function - predicted	FGFR2 H544Q lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). H544Q results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR1	N546K	missense	gain of function	FGFR1 N546K lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). N546K does not confer a growth advantage in a competition assay (PMID: 34272467), but results in increased Fgfr1 protein nuclear localization, Erk, Akt, and Stat3 phosphorylation (PMID: 35488346), and kinase activity, and is transforming in cultured cells (PMID: 26179511, PMID: 23817572, PMID: 29533785).
FGFR2	N549D	missense	gain of function - predicted	FGFR2 N549D lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549D results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467) and has been associated with resistance to Fgfr inhibitors in the context of an FGFR2 fusion in culture (PMID: 28034880), and therefore, is predicted to lead to a gain of Fgfr2 protein function.	Y
FGFR2	N549H	missense	gain of function	FGFR2 N549H lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549H demonstrates resistance to FGFR inhibitors in the context of FGFR2-CLIP1 in culture (PMID: 31371345), and confers a gain of function to the Fgfr2 protein as indicated by disengagement of autoinhibitory mechanisms thereby resulting in constitutive activation and downstream pathway activation (PMID: 17525745, PMID: 17803937), elevated kinase activity in substrate phosphorylation assays (PMID: 28166054), a growth advantage relative to wild-type Fgfr2 in a competition assay, and increased transformation activity in cultured cells (PMID: 34272467).	Y
FGFR2	N549K	missense	gain of function	FGFR2 N549K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549K confers a gain of function to the Fgfr2 protein resulting in a growth advantage relative to wild-type Fgfr2 in a competition assay, increased transformation activity in cultured cells (PMID: 34272467), oncogenic transformation in culture (PMID: 18552176, PMID: 17803937, PMID: 29533785) and increased MAPK pathway signaling in cultured cells (PMID: 19147536).	Y
FGFR2	N549S	missense	gain of function	FGFR2 N549S lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549S demonstrates increased transforming activity compared to wild-type Fgfr2 in culture (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	L560F	missense	gain of function - predicted	FGFR2 L560F lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L560F results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	P582L	missense	no effect - predicted	FGFR2 P582L lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). P582L results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR1	S588T	missense	no effect - predicted	FGFR1 S588T lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). S588T results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR1	E592G	missense	no effect - predicted	FGFR1 E592G lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). E592G results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function.
FGFR2	E596K	missense	no effect - predicted	FGFR2 E596K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E596K results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR3	R603Q	missense	no effect - predicted	FGFR3 R603Q lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R603Q results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR1	A604T	missense	loss of function - predicted	FGFR1 A604T lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). A604T results in decreased proliferation relative to wild-type Fgfr1 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr1 protein function.
FGFR2	G613S	missense	no effect - predicted	FGFR2 G613S lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). G613S results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR3	R621H	missense	no effect - predicted	FGFR3 R621H lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R621H results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	R625Q	missense	loss of function - predicted	FGFR2 R625Q lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). R625Q results in decreased proliferation compared to wild-type Fgfr2 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr2 protein function.
FGFR2	M640I	missense	no effect - predicted	FGFR2 M640I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). M640I results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function.
FGFR3	R640W	missense	no effect - predicted	FGFR3 R640W lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R640W results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR3	D641N	missense	gain of function - predicted	FGFR3 D641N lies within the TK-2 domain of the Fgfr3 protein (PMID: 19287463). D641N results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), but increased Fgfr3 autophosphorylation and substrate phosphorylation in culture (PMID: 26992226), and therefore, is predicted to lead to a gain of Fgfr3 protein function.
FGFR1	R646W	missense	loss of function - predicted	FGFR1 R646W lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). R646W results in decreased proliferation relative to wild-type Fgfr1 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr1 protein function.
FGFR2	A648T	missense	loss of function	FGFR2 A648T lies within the protein kinase domain of the Fgfr2 protein (PMID: 19147536). A648T confers a loss of function to the Fgfr2 protein demonstrated by decreased proliferation relative to wild-type Fgfr2 in a competition assay and decreased transformation activity (PMID: 34272467), decreaed protein kinase activity, and reduced downstream MAPK signaling pathway activation in cultured cells (PMID: 19147536).
FGFR3	K650E	missense	gain of function	FGFR3 K650E (also referred to as K652E from the FGFR3IIIb isoform) lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650E confers a gain of function to the Fgfr3 protein as demonstrated by constitutive activation (PMID: 11055896), a growth advantage in a competition assay (PMID: 34272467), and transformation of cells in culture (PMID: 11157491, PMID: 34272467).
FGFR3	K650M	missense	gain of function	FGFR3 K650M (also referred to as K652M from the FGFR3IIIb isoform) lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650M confers a gain of function to the Fgfr3 protein as demonstrated by ligand-dependent autophosphorylation, activation of Mapk signaling (PMID: 9857065), activation of Stat1 in kinase assays (PMID: 19088846), a growth advantage in a competition assay, and increased transformation activity in cultured cells (PMID: 34272467).
FGFR3	K650N	missense	gain of function	FGFR3 K650N lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650N confers a gain of function to the Fgfr3 protein as demonstrated by constitutive activation (PMID: 11055896), a growth advantage in a competition assay, and increased transformation activity in cultured cells (PMID: 34272467).
FGFR3	K650Q	missense	gain of function	FGFR3 K650Q (also referred to as K652Q from the FGFR3IIIb isoform) lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650Q confers a gain of function to the Fgfr3 protein as demonstrated by increased autophosphorylation in culture (PMID: 11055896), a growth advantage in a competition assay, and increased transformation activity in cultured cells (PMID: 34272467).
FGFR3	K650T	missense	gain of function	FGFR3 K650T (also referred to as K652T from the FGFR3IIIb isoform) lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650T confers a gain of function to the Fgfr3 protein as demonstrated by constitutive activation (PMID: 11055896), a growth advantage in a competition assay, and increased transformation activity in cultured cells (PMID: 34272467).
FGFR1	K656*	nonsense	loss of function - predicted	FGFR1 K656* results in a premature truncation of the Fgfr1 protein at amino acid 656 of 822 (UniProt.org). K656* results in decreased proliferation relative to wild-type Fgfr1 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr1 protein function.
FGFR1	K656E	missense	gain of function	FGFR1 K656E lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). K656E does not confer a growth advantage in a competition assay but confers a gain of function to the Fgfr1 protein as demonstrated by constitutive activation of MAPK signaling (PMID: 23817572), and is transforming in cultured cells (PMID: 23817572, PMID: 34272467).
FGFR1	K656M	missense	gain of function - predicted	FGFR1 K656M lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). K656M results in decreased proliferation relative to wild-type Fgfr1 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr1 protein function.
FGFR2	K659E	missense	gain of function	FGFR2 K659E (also referred to as K660E from the FGFR2IIIb isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K659E results in a growth advantage relative to wild-type Fgfr2 in a competition assay and increased transformation activity in cultured cells (PMID: 34272467), increased phosphorylation of downstream signaling molecules, induces colony formation in culture (PMID: 23786770), and results in the ability to induce senescence and cooperate with Myc to induce transformation of cell lines in culture (PMID: 19403560).
FGFR2	K659N	missense	gain of function	FGFR2 K659N (also referred to as K660N from the FGFR2IIIb isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K659N results in proliferation similar to wild-type Fgfr2 in a competition assay (PMID: 34272467) but confers a gain of function to the Fgfr2 protein as demonstrated by increased autophosphorylation and phosphorylation of downstream targets, Mek and Stat3 (PMID: 23527311), and increased transformation activity in cultured cells (PMID: 34272467).
FGFR2	R664W	missense	unknown	FGFR2 R664W lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). R664W results in a growth advantage relative to wild-type Fgfr2 in a competition assay but transformation activity similar to wild-type in cultured cells (PMID: 34272467), and decreased autophosphorylation compared to wild-type Fgfr2 in an in vitro kinase assay (PMID: 28151998), and therefore, its effect on Fgfr2 protein function is unknown.
FGFR1	V664L	missense	loss of function - predicted	FGFR1 V664L lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). V664L results in decreased proliferation relative to wild-type Fgfr1 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr1 protein function.
FGFR3	E686K	missense	no effect - predicted	FGFR3 E686K lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). E686K results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR3	T689M	missense	no effect - predicted	FGFR3 T689M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). T689M results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	E695K	missense	loss of function - predicted	FGFR2 E695K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E695K results in decreased proliferation relative to wild-type Fgfr2 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr2 protein function.
FGFR3	G697C	missense	no effect	FGFR3 G697C lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). G697C results in proliferation similar to wild-type Fgfr3 in a competition assay (PMID: 34272467), demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3, and is not transforming in cell culture (PMID: 26992226, PMID: 34272467).
FGFR1	G703S	missense	unknown	FGFR1 G703S lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). G703S results in decreased proliferation relative to wild-type Fgfr1 in a competition assay but transformation activity similar to wild-type Fgfr1 (PMID: 34272467), and therefore, its effect on Fgfr1 protein function is unknown.
FGFR2	P708S	missense	loss of function - predicted	FGFR2 P708S lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). P708S results in decreased proliferation relative to wild-type Fgfr2 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr2 protein function.
FGFR3	P716H	missense	no effect - predicted	FGFR3 P716H lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). P716H results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR2	E718K	missense	gain of function - predicted	FGFR2 E718K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E718K results in decreased proliferation relative to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR2	M722I	missense	loss of function - predicted	FGFR2 M722I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). M722I results in decreased proliferation relative to wild-type Fgfr2 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr2 protein function.
FGFR1	V751A	missense	loss of function - predicted	FGFR1 V751A lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). V751A results in decreased proliferation relative to wild-type Fgfr1 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr1 protein function.
FGFR2	S791T	missense	gain of function - predicted	FGFR2 S791T lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). S791T results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
FGFR1	R809Q	missense	unknown	FGFR1 R809Q lies within the cytoplasmic domain of the Fgfr1 protein (UniProt.org). R809Q results in decreased proliferation relative to wild-type Fgfr1 in a competition assay but transformation activity similar to wild-type Fgfr1 in culture (PMID: 34272467), and therefore, its effect on Fgfr1 protein function is unknown.

Showing 1 to 134 of 134 entries

Filter rows:

Showing 1 to 529 of 529 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FGFR1 N546K	Advanced Solid Tumor	predicted - resistant	Erdafitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with Balversa (erdafitinib) in culture, and Balversa (erdafitinib) treatment did not lead to tumor growth inhibition in a cell line xenograft model (PMID: 34272467).	34272467
FGFR2 N549K	Advanced Solid Tumor	resistant	Erdafitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, cells expressing FGFR2 N549K were resistant to treatment with Balversa (erdafitinib) in culture and cell line xenograft models (PMID: 34272467).	34272467
FGFR2 N549K	Advanced Solid Tumor	conflicting	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, cells expressing FGFR2 N549K did not demonstrate sensitivity to treatment with E7090 in culture, but E7090 treatment led to inhibition of tumor growth in a cell line xenograft model (PMID: 34272467).	34272467
FGFR3 K650N	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, cells expressing FGFR3 K650N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability, and Balversa (erdafitinib) treatment led to inhibition of tumor growth in a cell line xenograft model (PMID: 34272467).	34272467
FGFR3 K650N	Advanced Solid Tumor	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, cells expressing FGFR3 K650N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability, and E7090 treatment led to inhibition of tumor growth in a cell line xenograft model (PMID: 34272467).	34272467
FGFR1 A121D	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A121D	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A121D	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A121D	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A121D	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A121D were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR1 A121D	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A121D	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A21T	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A21T	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A21T	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A21T	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A21T	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A21T	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A268S	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A268S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A268S	Advanced Solid Tumor	predicted - resistant	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A268S were resistant to treatment with E7090 in culture (PMID: 34272467).	34272467
FGFR1 A268S	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A268S were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A268S	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A268S were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 A268S	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 A268S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128N	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128N	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128N were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128N	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128N	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128N	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128N were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128V	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128V	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128V	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128V	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128V	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D128V	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D133N	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D133N	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D133N	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D133N	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D133N	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D133N	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D320N	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D320N	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D320N	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D320N	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D320N	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 D320N	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E467K	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E467K	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E467K	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E467K	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E467K	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E467K	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E592G	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E592G were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E592G	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E592G were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E592G	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E592G were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E592G	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E592G were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 E592G	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 E592G were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 G703S	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 G703S were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 G703S	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 G703S were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 G703S	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 G703S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 G703S	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 G703S were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 G703S	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 G703S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 K656E	Advanced Solid Tumor	conflicting	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 K656E were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 K656E	Advanced Solid Tumor	conflicting	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 K656E were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 K656E	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 K656E were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR1 K656E	Advanced Solid Tumor	conflicting	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 K656E were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 K656M	Advanced Solid Tumor	predicted - resistant	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 K656M were resistant to treatment with AZD4547 in culture (PMID: 34272467).	34272467
FGFR1 K656M	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 K656M were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR1 K656M	Advanced Solid Tumor	predicted - resistant	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 K656M were resistant to treatment with E7090 in culture (PMID: 34272467).	34272467
FGFR1 M456V	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 M456V were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR1 M456V	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 M456V	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 M456V	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 M456V	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 M456V	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 M456V	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 N546K	Advanced Solid Tumor	predicted - resistant	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with Truseltiq (infigratinib) in culture (PMID: 34272467).	34272467
FGFR1 N546K	Advanced Solid Tumor	predicted - resistant	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with AZD4547 in culture (PMID: 34272467).	34272467
FGFR1 N546K	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR1 N546K	Advanced Solid Tumor	predicted - resistant	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with Lytgobi (futibatinib) in culture (PMID: 34272467).	34272467
FGFR1 N546K	Advanced Solid Tumor	predicted - resistant	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with Pemazyre (pemigatinib) in culture (PMID: 34272467).	34272467
FGFR1 P150S	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 P150S were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 P150S	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 P150S were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 P150S	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 P150S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 P150S	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 P150S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 P483L	Advanced Solid Tumor	predicted - resistant	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 P483L were resistant to treatment with Lytgobi (futibatinib) in culture (PMID: 34272467).	34272467
FGFR1 P483L	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 P483L were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 P483L	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 P483L were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 P483L	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 P483L were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 P483L	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 P483L were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 P483L	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 P483L were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R189C	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R189C were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R189C	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R189C were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R189C	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R189C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR1 R250W	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R250W	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R250W	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R250W	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R250W	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R250W	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R445W	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R445W were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R445W	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R445W were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R445W	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R445W were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R445W	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R445W were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R445W	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R445W were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R475Q	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R475Q were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R475Q	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R475Q were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R475Q	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R475Q were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R475Q	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R475Q were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R809Q	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R809Q	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R809Q	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R809Q	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R809Q	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 R809Q	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S125L	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S125L	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S125L	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S125L	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S125L were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR1 S125L	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S125L	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S125L	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S238N	Advanced Solid Tumor	predicted - resistant	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S238N were resistant to treatment with AZD4547 in culture (PMID: 34272467).	34272467
FGFR1 S238N	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S238N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S238N	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S238N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S238N	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S238N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S238N	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S238N were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR1 S238N	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S238N were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S238N	Advanced Solid Tumor	predicted - resistant	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S238N were resistant to treatment with Truseltiq (infigratinib) in culture (PMID: 34272467).	34272467
FGFR1 S436F	Advanced Solid Tumor	predicted - resistant	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S436F were resistant to treatment with E7090 in culture (PMID: 34272467).	34272467
FGFR1 S436F	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S436F were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S436F	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S436F were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S436F	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S436F were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S436F	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S436F were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S436F	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S436F were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S588T	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S588T were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S588T	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S588T were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S588T	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S588T were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S588T	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S588T were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 S588T	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 S588T were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T141R	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T141R	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T141R	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T141R	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T141R	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T26I	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T26I were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T26I	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T26I were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T26I	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T26I were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T26I	Advanced Solid Tumor	predicted - sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T26I were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR1 T26I	Advanced Solid Tumor	predicted - resistant	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T26I were resistant to treatment with AZD4547 in culture (PMID: 34272467).	34272467
FGFR1 T26I	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T26I were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T319A	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T319A	Advanced Solid Tumor	predicted - resistant	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T319A were resistant to treatment with E7090 in culture (PMID: 34272467).	34272467
FGFR1 T319A	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T319A were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR1 T319A	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T319A	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T319A	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T340M	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T340M	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T340M	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T340M	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T340M	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T340M	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 V751A	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 V751A	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 V751A	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 V751A	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 V751A	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 V751A	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A264T	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A264T were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A264T	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A264T were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A264T	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A264T were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 A264T	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A264T were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A264T	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A264T were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A264T	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A264T were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A264T	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A264T were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A371V	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A371V were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A371V	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A371V were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A371V	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A371V were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A371V	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A371V were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A371V	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A371V were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A371V	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A371V were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A389T	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A389T	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A389T	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A389T	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A389T	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A389T	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A67V	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A67V were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A67V	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A67V were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A67V	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A67V were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A67V	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A67V were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A67V	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A67V were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 A67V	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 A67V were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C62Y	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C62Y were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C62Y	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C62Y were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C62Y	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C62Y were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 C62Y	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C62Y were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C62Y	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C62Y were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C62Y	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C62Y were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C62Y	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C62Y were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 D101Y	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 D101Y	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 D101Y	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 D101Y	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 D101Y	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 D101Y were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 D101Y	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 D101Y	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E160K	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E160K were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E160K	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E160K were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E160K	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E160K were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E160K	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E160K were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E160K	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E160K were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 E160K	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E160K were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E160K	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E160K were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E163K	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E163K were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E163K	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E163K were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E163K	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E163K were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E163K	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E163K were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E163K	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E163K were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E163K	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E163K were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 E163K	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E163K were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E475K	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E475K were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E475K	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E475K were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E475K	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E475K were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E475K	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E475K were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E475K	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E475K were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E475K	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E475K were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E596K	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E596K were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E596K	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E596K were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E596K	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E596K were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E596K	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E596K were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E596K	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E596K were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E596K	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E596K were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E718K	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E718K were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E718K	Advanced Solid Tumor	predicted - sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E718K were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 E718K	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E718K were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E718K	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E718K were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E718K	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E718K were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 E718K	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 E718K were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G227E	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G227E were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 G227E	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G227E	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G227E	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G227E	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G227E	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G227E	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G305R	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G305R were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G305R	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G305R were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G305R	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G305R were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G305R	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G305R were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 G305R	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G305R were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G305R	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G305R were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G305R	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G305R were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G364E	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G364E were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G364E	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G364E were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G364E	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G364E were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G364E	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G364E were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G364E	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G364E were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G364E	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G364E were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G613S	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G613S were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 G613S	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G613S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G613S	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G613S were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G613S	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G613S were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G613S	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G613S were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G613S	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G613S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 G613S	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 G613S were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H242Y	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H242Y were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H242Y	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H242Y were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H242Y	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H242Y were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H242Y	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H242Y were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H242Y	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H242Y were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H242Y	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H242Y were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H416R	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H416R were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H416R	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H416R were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H416R	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H416R were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H416R	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H416R were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H416R	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H416R were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H416R	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H416R were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H544Q	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H544Q were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H544Q	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H544Q were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H544Q	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H544Q were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H544Q	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H544Q were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 H544Q	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H544Q were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H544Q	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H544Q were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 H544Q	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 H544Q were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 I422V	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 I422V were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 I422V	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 I422V were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 I422V	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 I422V were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 I422V	Advanced Solid Tumor	predicted - sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 I422V were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 I422V	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 I422V were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 I422V	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 I422V were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 I422V	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 I422V were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K310R	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K310R were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K310R	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K310R were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K310R	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K310R were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 K310R	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K310R were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K310R	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K310R were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K310R	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K310R were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K310R	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K310R were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K659E	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659E were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 K659E	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659E were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K659E	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659E were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K659E	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659E were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K659N	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K659N	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659N were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K659N	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659N were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K659N	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659N were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 K659N	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K659N	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659N were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 K659N	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 K659N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L33S	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L33S	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L33S	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L33S	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L33S were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 L33S	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L33S	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L33S	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L560F	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L560F were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L560F	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L560F were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L560F	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L560F were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L560F	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L560F were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L560F	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L560F were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 L560F	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 L560F were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M186T	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M186T were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M186T	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M186T were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M186T	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M186T were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M186T	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M186T were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 M186T	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M186T were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M186T	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M186T were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M186T	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M186T were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M640I	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M640I were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M640I	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M640I were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M640I	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M640I were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M640I	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M640I were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M640I	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M640I were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 M640I	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 M640I were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N549D	Advanced Solid Tumor	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549D were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N549D	Advanced Solid Tumor	resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549D were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 N549D	Advanced Solid Tumor	resistant	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549D were resistant to treatment with Truseltiq (infigratinib) in culture (PMID: 34272467).	34272467
FGFR2 N549D	Advanced Solid Tumor	resistant	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549D were resistant to treatment with AZD4547 in culture (PMID: 34272467).	34272467
FGFR2 N549D	Advanced Solid Tumor	resistant	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549D were resistant to treatment with Pemazyre (pemigatinib) in culture (PMID: 34272467).	34272467
FGFR2 N549D	Advanced Solid Tumor	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549D were resistant to treatment with Balversa (erdafitinib) in culture (PMID: 34272467).	34272467
FGFR2 N549H	Advanced Solid Tumor	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549H were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N549H	Advanced Solid Tumor	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549H were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N549K	Advanced Solid Tumor	resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549K were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 N549K	Advanced Solid Tumor	resistant	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549K were resistant to treatment with Pemazyre (pemigatinib) in culture (PMID: 34272467).	34272467
FGFR2 N549K	Advanced Solid Tumor	resistant	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549K were resistant to treatment with Truseltiq (infigratinib) in culture (PMID: 34272467).	34272467
FGFR2 N549K	Advanced Solid Tumor	resistant	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549K were resistant to treatment with AZD4547 in culture (PMID: 34272467).	34272467
FGFR2 N549S	Advanced Solid Tumor	sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N549S	Advanced Solid Tumor	resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549S were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 N549S	Advanced Solid Tumor	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549S were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N549S	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549S were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N549S	Advanced Solid Tumor	sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N549S	Advanced Solid Tumor	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N549S were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N82K	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N82K	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N82K	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N82K	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N82K	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 N82K	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253L	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253L were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253L	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253L were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253L	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253L were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253L	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253L were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253L	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253L were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 P253L	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253L were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253L	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253L were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253R	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253R were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253R	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253R were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253R	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253R were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253R	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253R were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 P253R	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253R were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253R	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253R were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P253R	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P253R were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P303L	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P303L were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P303L	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P303L were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P303L	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P303L were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P303L	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P303L were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 P303L	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P303L were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P303L	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P303L were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P303L	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P303L were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P582L	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P582L were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P582L	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P582L were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P582L	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P582L were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P582L	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P582L were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P582L	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P582L were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 P582L	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 P582L were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Q212K	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Q212K were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Q212K	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Q212K were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Q212K	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Q212K were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Q212K	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Q212K were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Q212K	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Q212K were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 Q212K	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Q212K were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Q212K	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Q212K were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203C	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203C were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203C	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 R203C	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203C were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203C	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203C were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203C	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203C were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203C	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203C were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203C	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203C were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203H	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203H were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203H	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203H were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203H	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203H were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203H	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203H were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203H	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203H were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R203H	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R203H were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R210Q	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R210Q were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R210Q	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R210Q were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R210Q	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R210Q were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R210Q	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R210Q were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R210Q	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R210Q were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R210Q	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R210Q were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R251Q	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R251Q were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R251Q	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R251Q were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R251Q	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R251Q were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R251Q	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R251Q were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R251Q	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R251Q were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R251Q	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R251Q were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R330W	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R330W	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R330W	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R330W were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 R330W	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R330W	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R330W	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R330W	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R399Q	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R399Q were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R399Q	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R399Q were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R399Q	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R399Q were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R399Q	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R399Q were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R399Q	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R399Q were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R399Q	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R399Q were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R664W	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R664W were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R664W	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R664W were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R664W	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R664W were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R664W	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R664W were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R664W	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R664W were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R664W	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R664W were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R6P	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R6P were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R6P	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R6P were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R6P	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R6P were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R6P	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R6P were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R6P	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R6P were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 R6P	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R6P were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 R6P	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 R6P were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	conflicting	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S791T	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S791T were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S791T	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S791T were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S791T	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S791T were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S791T	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S791T were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S791T	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S791T were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 S791T	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S791T were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S791T	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S791T were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 V392A	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 V392A were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 V392A	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 V392A were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 V392A	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 V392A were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 V392A	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 V392A were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 V392A	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 V392A were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 V392A	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 V392A were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 W290C	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 W290C were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 W290C	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 W290C were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 W290C	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 W290C were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 W290C	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 W290C were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 W290C	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 W290C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 Y328N	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y328N were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 Y328N	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y328N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y328N	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y328N were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y328N	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y328N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y328N	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y328N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y328N	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y328N were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y328N	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y328N were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 A391E	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 A391E were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 A391E	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 A391E were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 A391E	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 A391E were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 A391E	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 A391E were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 A391E	Advanced Solid Tumor	predicted - sensitive	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 A391E were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 G370C	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G370C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 G370C	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G370C were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 G370C	Advanced Solid Tumor	predicted - resistant	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G370C were resistant to treatment with E7090 in culture (PMID: 34272467).	34272467
FGFR3 G380E	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G380E were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 G380E	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G380E were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 G380E	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G380E were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 G380E	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G380E were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 G380R	Advanced Solid Tumor	predicted - sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G380R were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 G380R	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G380R were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 G380R	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G380R were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 G380R	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 G380R were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 H284fs	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 H284fs (FGFR3 H284fs*10) were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 H284fs	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 H284fs (FGFR3 H284fs*10) were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 H284fs	Advanced Solid Tumor	predicted - resistant	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 H284fs (FGFR3 H284fs*10) were resistant to treatment with E7090 in culture (PMID: 34272467).	34272467
FGFR3 H284fs	Advanced Solid Tumor	predicted - resistant	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 H284fs (FGFR3 H284fs*10) were resistant to treatment with Pemazyre (pemigatinib) in culture (PMID: 34272467).	34272467
FGFR3 K650E	Advanced Solid Tumor	conflicting	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 K650E were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 K650M	Advanced Solid Tumor	resistant	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 K650M were resistant to treatment with AZD4547 in culture (PMID: 34272467).	34272467
FGFR3 K650M	Advanced Solid Tumor	resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 K650M were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 K650N	Advanced Solid Tumor	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 K650N were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 K650N	Advanced Solid Tumor	sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 K650N were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 K650N	Advanced Solid Tumor	sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 K650N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 K650T	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 K650T were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 R248_S249insC	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 R248_S249insC were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 R248_S249insC	Advanced Solid Tumor	predicted - resistant	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 R248_S249insC were resistant to treatment with E7090 in culture (PMID: 34272467).	34272467
FGFR3 R248C	Advanced Solid Tumor	conflicting	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 R248C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 S249C	Advanced Solid Tumor	predicted - resistant	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 S249C were resistant to treatment with E7090 in culture (PMID: 34272467).	34272467
FGFR3 S249C	Advanced Solid Tumor	conflicting	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 S249C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 S371C	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 S371C were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR3 S371C	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 S371C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 Y373C	Advanced Solid Tumor	predicted - resistant	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 Y373C were resistant to treatment with E7090 in culture (PMID: 34272467).	34272467
FGFR3 Y373C	Advanced Solid Tumor	predicted - resistant	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 Y373C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR3 Y373C	Advanced Solid Tumor	predicted - sensitive	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR3 Y373C were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR1 T141R	Advanced Solid Tumor	predicted - sensitive	Pemigatinib	Preclinical	Actionable	In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467

Showing 1 to 529 of 529 entries

Filter rows:

Reference Detail

Contact

Filtering

Sorting